Sea

Seagen is a global biotechnology company that specializes in the development and commercialization of targeted therapies for cancer. The company is a pioneer in antibody-drug conjugate (ADC) technology, which combines the specificity of monoclonal antibodies with the potency of cytotoxic agents to selectively eliminate cancer cells while sparing healthy tissue. Seagen's portfolio includes several FDA-approved products such as Adcetris, Padcev, Tivdak, and Tukysa, addressing various hematologic malignancies and solid tumors. In December 2023, the company was acquired by Pfizer for approximately $43 billion, significantly expanding Pfizer's oncology pipeline and manufacturing capabilities.